NGT | iIFG | iIGT | |||
OR (95% CI) | P value | OR (95% CI) | P value | ||
Central obesity | 1 (ref.) | 1.08 (0.23 to 5.13) | 0.924 | 2.44 (0.71 to 8.35) | 0.156 |
BP≥130/85 mm Hg | 1 | 2.41 (0.86 to 6.76) | 0.095 | 3.99 (1.46 to 10.93) | 0.007 |
TG≥1.7 mmol/L | 1 | 0.91 (0.28 to 3.00) | 0.876 | 2.40 (0.95 to 6.07) | 0.065 |
HDL-C<1.04 mmol/L | 1 | 0.36 (0.05 to 2.97) | 0.345 | 0.78 (0.20 to 3.05) | 0.721 |
HOMA-IR >3.0 | 1 | 3.50 (1.19 to 10.30) | 0.023 | 3.65 (1.37 to 9.73) | 0.010 |
Metabolic syndrome | 1 | 1.36 (0.33 to 5.64) | 0.674 | 32.60 (9.66 to 110.02) | <0.001 |
NAFLD | |||||
Mild | 1 | 2.17 (0.65 to 7.26) | 0.208 | 1.10 (0.24 to 4.95) | 0.902 |
Moderate to severe | 1 | 5.31 (0.71 to 39.41) | 0.103 | 6.29 (1.04 to 37.86) | 0.045 |
Logistic regression models were used with adjustment for age, gender and body mass index.
P values in bold are significant at p<0.05.
BP, blood pressure; HDL-C, high-density lipoprotein cholesterol; HOMA-IR, homeostasis model assessment of insulin resistance; iIFG, isolated impaired fasting glucose; iIGT, isolated impaired glucose tolerance; NAFLD, non-alcoholic fatty liver disease; NGT, normal glucose tolerance; ref., reference; TG, triglyceride.